## **Core Concept**
Nephrogenic Diabetes Insipidus (NDI) is a condition characterized by the kidneys' inability to concentrate urine due to a defect in the renal tubules' response to antidiuretic hormone (ADH), also known as vasopressin. This results in the production of large volumes of diluted urine. The mainstay of treatment focuses on managing the underlying cause and symptomatically reducing polyuria.

## **Why the Correct Answer is Right**
The correct answer, , involves the use of thiazide diuretics, which paradoxically decrease urine output in patients with NDI. Thiazides work by inducing mild volume contraction, which enhances proximal tubular sodium and water reabsorption, reducing the delivery of filtrate to the diluting segment of the nephron. This results in decreased urine volume. Additionally, thiazides can be used in combination with other treatments like **amiloride** or **indomethacin** to enhance their effect.

## **Why Each Wrong Option is Incorrect**
- **Option A:** - This option is incorrect because while **desmopressin**, a synthetic analogue of ADH, is effective in treating central diabetes insipidus, it is not effective in nephrogenic diabetes insipidus since the kidneys in NDI are unresponsive to ADH.
- **Option B:** - This option is incorrect because **lithium** is actually a cause of nephrogenic diabetes insipidus. It interferes with ADH signaling in the collecting ducts.
- **Option C:** - This option might seem plausible but is not the mainstay of treatment.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that the treatment of NDI often involves **thiazide diuretics** (paradoxically), **potassium-sparing diuretics** like amiloride, and **NSAIDs** like indomethacin, which can enhance the concentrating ability of the kidneys. A classic clinical correlation is that patients with NDI should be advised to restrict their **sodium intake** to minimize polyuria.

## **Correct Answer:** .